Blueprint Collaborated with Proteovant to Advance Novel Targeted Protein Degrader Therapies
Shots:
- Proteovant to receive a $20M up front & will be eligible to receive an additional ~$632M in milestones including $105M in preclinical, clinical & regulatory milestones & $527M in approval & sales milestones along with royalties on the first two program targets
- Blueprint gets an exclusive option to develop & commercialize the product. Proteovant gets an option to co-develop & co-commercialize the second of the two Blueprint optioned programs in the US
- The collaboration will use Proteovant’s AI-enhanced targeted protein degradation platform & Blueprint’s precision medicine capabilities to discover targeted protein degraders in oncology & hematology
Ref: Blueprint Medicines | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
